Matinas BioPharma Holdings, Inc. announced that its Board of Directors approved a one-for-fifteen (1:15) reverse stock split of its common stock. The action was authorized by shareholders in June 2025 and is intended to help maintain compliance with NYSE American listing requirements. The split becomes effective at 12:01 a.m. Eastern Time on September 28, 2026, with trading resuming on the same date under the existing symbol MTNB. Fractional shares will be cashed out rather than issued. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases and cancer.

Matinas BioPharma Holdings, Inc. received a notice from the NYSE American on August 31, 2026, stating it is not in compliance with continued listing standards requiring stockholders' equity of at least $2.0 million. The company reported stockholders’ equity of $1.8 million as of June 30, 2026, and has incurred losses from continuing operations or net losses in its five most recent fiscal years. This noncompliance relates to Section 1003(a)(i) of the NYSE American Company Guide, adding to existing notices regarding Sections 1003(a)(ii) and (iii). The company submitted a compliance plan on May 4, 2026, which was accepted by the exchange. Matinas has until October 2, 2027, to regain compliance or face delisting proceedings. The notice does not immediately impact trading, which continues under symbol MTNB with a .BC indicator. Matinas BioPharma is a biopharmaceutical company focused on delivering therapies using its lipid nanocrystal platform technology.

On July 23, 2026, Matinas BioPharma Holdings, Inc. announced the immediate termination of its $50,000,000 At-The-Market Sales Agreement with BTIG, LLC, which was originally entered into on July 2, 2020. The company is not subject to any termination penalties or expenses. Matinas BioPharma Holdings, Inc. is a biopharmaceutical company focused on its proprietary LNP-RNA platform.</div>

Matinas BioPharma Holdings, Inc. entered into a Business Combination Agreement with GH Power Inc. to merge, expected to close in Q4 2026. Under the agreement, Matinas common stockholders will receive 0.1 shares of Pubco common stock for each share held. Concurrently, the company entered into a Stock Purchase Agreement with Azurity Pharmaceuticals, Inc. for the sale of its subsidiary, Matinas Nano, for up to $21.5 million. Additionally, the company closed a $575,000 private placement of Series D Convertible Preferred Stock and a warrant inducement transaction that raised approximately $2.6 million. Matinas BioPharma Holdings, Inc. is a biopharmaceutical company focused on drug delivery technologies.

Matinas BioPharma Holdings, Inc. received a June 24, 2026, notice from the NYSE American LLC that it is non-compliant with stockholders' equity listing standards. The company's stockholders' equity was $3,022,000 as of March 31, 2026, falling below the required $4.0 million threshold. The NYSE American has accepted the company's plan to regain compliance, granting a plan period through October 2, 2027, to meet the requirements. Matinas BioPharma Holdings, Inc. is a biopharmaceutical company focused on developing RNA-based therapeutics.